Puma Biotechnology meldet Zahlen für Q1/19
- Umsatz 99 Mio. $
- Produktumsatz 46 Mio. $
- Lizenzumsatz 53 Mio. $
- Verlust 10 Mio. $
“Puma experienced lower than expected net product revenue in the first quarter of 2019,” said Alan H. Auerbach, Chairman, Chief Executive Officer and President of Puma. “This reduction in net revenues was the result of an increase in expenses charged against gross revenue for the quarter. Additionally, net product revenue declined in the quarter as a result of an increase in patients discontinuing treatment with NERLYNX.”
Mr. Auerbach added, “During 2019, we anticipate the following key milestones for Puma:
(i) presenting data from the Phase III trial of neratinib in third-line metastatic breast cancer patients in the second quarter of 2019;
(ii) filing a new drug application for neratinib based on the results of the Phase III trial in third-line metastatic breast cancer in the summer of 2019;
(iii) meeting with the FDA to discuss the clinical development and regulatory strategy for the SUMMIT trial in the summer of 2019;
(iv) receiving regulatory decisions for the extended adjuvant HER2-positive early stage breast cancer indication in other countries in the second half of 2019;
(v) reporting additional data from the Phase II CONTROL trial in the second quarter of 2019; and
(vi) reporting Phase II data from the SUMMIT basket trial in patients with HER2 mutations in the second half of 2019.”
https://investor.pumabiotechnology.com/...rter-2019-financial-results
|
Thread abonnieren
